Treatment Patterns, Adverse Events, and Clinical Outcomes with Steroidal Mineralocorticoid Receptor Antagonists: A Retrospective Analysis of Administrative Claims Data (RELICS)

Emma L Richard,1 Nihar R Desai,2 Vincent J Willey,1 Alain Gay,3 Charlie Scott,4 Kerstin Folkerts,5 Elena Pessina,6 Rakesh Singh,7 Chia-Chen Teng,1 Nikolaus G Oberprieler8 1Health Economics and Outcomes Research, Carelon Research, Wilmington, DE, USA; 2Department of Cardiovascular Medicine, Yale Scho...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Pragmatic and Observational Research
المؤلفون الرئيسيون:	Richard EL, Desai NR, Willey VJ, Gay A, Scott C, Folkerts K, Pessina E, Singh R, Teng CC, Oberprieler NG
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Dove Medical Press 2025-02-01
الموضوعات:	steroidal mineralocorticoid receptor antagonists treatment patterns adverse events clinical outcomes real-world data administrative claims
الوصول للمادة أونلاين:	https://www.dovepress.com/treatment-patterns-adverse-events-and-clinical-outcomes-with-steroidal-peer-reviewed-fulltext-article-POR

مواد مشابهة

Steroidal Mineralocorticoid Receptor Antagonist Side Effects and Reasons for Discontinuation: A Patient Survey (RELICS-PS)
حسب: Richard EL, وآخرون
منشور في: (2025-04-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
حسب: Sofia S. Pereira, وآخرون
منشور في: (2021-04-01)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
حسب: Ulrich Kintscher, وآخرون
منشور في: (2023-06-01)

Effectiveness and safety of mineralocorticoid receptor antagonists in heart failure patients with and without diabetes: a systematic review and meta-analysis
حسب: Arga Setyo Adji, وآخرون
منشور في: (2024-11-01)

Heart failure: the role for mineralocorticoid receptor antagonists
حسب: Bertram Pitt
منشور في: (2014-05-01)

Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists
حسب: Biykem Bozkurt, وآخرون
منشور في: (2025-07-01)

A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
حسب: Shuhui Zhai, وآخرون
منشور في: (2024-09-01)

In Silico Investigation of Mineralocorticoid Receptor Antagonists: Insights into Binding Mechanisms and Structural Dynamics
حسب: Julia J. Liang, وآخرون
منشور في: (2025-03-01)

Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue
حسب: WEN Runzhi, WANG Li, ZHAO Naiqian
منشور في: (2025-06-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
حسب: S. R. Gilyarevsky, وآخرون
منشور في: (2023-10-01)

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases
حسب: Jiao Wang, وآخرون
منشور في: (2025-08-01)

MINERALOCORTICOID RECEPTOR ANTAGONISTS THERAPY IN RESISTANT HYPERTENSION: TIME TO IMPLEMENT NEW GUIDELINES?
حسب: Giuseppe eMaiolino, وآخرون
منشور في: (2015-02-01)

Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
حسب: S N Tereshchenko, وآخرون
منشور في: (2013-12-01)

Assessment of renal and cardiovascular risks in patients with type 2 diabetes when using non-steroidal mineralocorticoid receptor antagonists
حسب: V.М. Yerokhovych, وآخرون
منشور في: (2023-12-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
حسب: Nina Vodošek Hojs, وآخرون
منشور في: (2021-06-01)

The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist’s treatment: A review
حسب: Irina N. Bobkova
منشور في: (2023-11-01)

Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients
حسب: Takuro Abe, وآخرون
منشور في: (2020-10-01)

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
حسب: A. M. Esayan, وآخرون
منشور في: (2018-04-01)

Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment
حسب: Mohamad El Wardani, وآخرون
منشور في: (2023-03-01)

Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice
حسب: Maria Alfarano, MD, PhD, وآخرون
منشور في: (2025-06-01)

Endogenous bufadienolides, mineralocorticoid receptor antagonists and fibrosis in chronic kidney disease
حسب: Mai Rosenberg, وآخرون
منشور في: (2024-09-01)

Expression of genes encoding mineralocorticoid biosynthetic enzymes and the mineralocorticoid receptor, and levels of mineralocorticoids in the bovine follicle and corpus luteum
حسب: Memory MUKANGWA, وآخرون
منشور في: (2019-12-01)

Focus on Finerenone, a Non-Steroidal MRA in Diabetic Kidney Disease. What Physicians Should Know?
حسب: Dwaipayan Sarathi CHAKRABORTY, وآخرون
منشور في: (2022-03-01)

Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis
حسب: Xinrui Jiang, وآخرون
منشور في: (2022-06-01)

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
حسب: O. A. Osipova, وآخرون
منشور في: (2021-11-01)

Mineralocorticoid receptor antagonists reduce inflammatory signaling independent of myofiber mineralocorticoid receptor
حسب: Jeovanna Lowe, وآخرون
منشور في: (2025-12-01)

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease
حسب: Ixchel Lima Posada, وآخرون
منشور في: (2024-06-01)

Adrenal venous sampling outcomes with and without mineralocorticoid receptor antagonists in primary aldosteronism
حسب: Sittikul Thipbumrung, وآخرون
منشور في: (2025-07-01)

Chemokine receptor CXCR7 antagonism ameliorates cardiac and renal fibrosis induced by mineralocorticoid excess
حسب: Bing H. Wang, وآخرون
منشور في: (2024-11-01)

Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis
حسب: Chien‐Wei Huang, وآخرون
منشور في: (2025-02-01)

Recent Advances and Perspectives on the Use of Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Chronic Kidney Disease: A Review
حسب: Kisho Miyasako, وآخرون
منشور في: (2024-12-01)

Chemical Structure, Classification and Clinical Significance of Steroid Hormones: A Review Article
حسب: Rasha M. Kamil, وآخرون
منشور في: (2025-08-01)

Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study
حسب: Michael Blankenburg, وآخرون
منشور في: (2019-05-01)

Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat
حسب: Chang Geng, وآخرون
منشور في: (2023-11-01)

Clinical application of mineralocorticoid receptor antagonists in chronic heart failure
حسب: MG Bubnova
منشور في: (2014-12-01)

Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?
حسب: Houry Puzantian, وآخرون
منشور في: (2024-12-01)

FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes
حسب: M. S. Shamkhalova, وآخرون
منشور في: (2023-12-01)

Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis
حسب: Yue Zhang, وآخرون
منشور في: (2025-09-01)

Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials
حسب: Paula Dibo, وآخرون
منشور في: (2025-08-01)

Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K/Akt/eNOS signaling pathway in diabetic tubulopathy
حسب: Lan Yao, وآخرون
منشور في: (2023-12-01)